Send to

Choose Destination
Drug News Perspect. 2008 May;21(4):218-24. doi: 10.1358/dnp.2008.21.4.1213351.

Lysyl oxidase as a potential therapeutic target.

Author information

Centro de Investigacion Cardiovascular (CSIC-ICCC), Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.


Lysyl oxidase (LOX) is a copper-dependent amine oxidase that catalyzes the covalent cross-link of collagens and elastin in the extracellular environment, thereby determining the mechanical properties of extracellular matrix (ECM) and connective tissues. ECM remodeling is a common feature of diverse pathologic processes. Therefore, dysregulation of LOX could underlie the onset and progression of multiple pathologies affecting connective tissue, such as fibrotic processes, tumor progression and metastasis and neurodegenerative and cardiovascular diseases. Here we review clinical and experimental evidence that supports a role for LOX in the pathophysiology of those processes and point out LOX as a potential therapeutic target.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Clarivate Analytics
Loading ...
Support Center